UQ Researchers Develop First Drug Targeting Elusive C5aR2 Receptor, Paving Path to Transform MND into a Manageable Chronic Condition
核心洞察
University of Queensland (搜索) researchers developed R8Y (搜索), the first drug to successfully target the immune receptor C5aR2 (搜索), unlocking its molecular structure and role in inflammation.
The breakthrough could lead to anti-inflammatory drug testing in motor neurone disease (搜索) patients within five years, potentially transforming MND from a terminal illness into a chronic condition.
The international collaboration spanning Australia, Japan, South Korea, India, and Europe revealed C5aR2 (搜索) does not couple to G proteins, explaining why it has been so difficult to target.
An international research team led by the University of Queensland (搜索) has achieved a world-first breakthrough in motor neurone disease (搜索) research, developing a drug that successfully targets a notoriously elusive immune receptor implicated in neuroinflammation. The discovery opens the door to anti-inflammatory treatments that could, within five years, transform MND from an acutely terminal illness into a manageable chronic condition.
The drug, called R8Y (搜索), specifically binds to C5aR2 (搜索), an immune cell receptor that has frustrated researchers for years due to its unusual behavior. By locking onto this receptor, scientists were able to determine its molecular structure for the first time and uncover its role in driving the inflammatory damage that accelerates neurodegenerative diseases.
"This allowed us to see the structure and function of the receptor which led to the discovery that C5aR2 (搜索) does not behave like most other receptors," said Professor Trent Woodruff from the UQ School of Biomedical Sciences. "It is unable to couple to G proteins — a rare and important distinction which explains why it's been so difficult to target and why its role in inflammation has been so elusive."
A New Mechanism for Controlling Neuroinflammation
The inability of C5aR2 (搜索) to couple to G proteins represents a fundamental departure from typical receptor biology. Most cell surface receptors rely on G protein signaling to transmit messages, but C5aR2 operates through an alternative mechanism. This unusual characteristic had rendered it effectively invisible to conventional drug discovery approaches.
"Using the drug we created, our international partners created a model of the drug bound to the receptor, giving us vital information around how the drug binds to the receptor and how the receptor signals," Professor Woodruff explained.
By understanding this binding mechanism, the UQ team is now positioned to develop improved anti-inflammatory drugs specifically designed for hard-to-treat neurodegenerative conditions, including motor neurone disease (搜索), Parkinson's disease (搜索), and Alzheimer's disease (搜索).
"The drug, by binding to this receptor, can limit the amount of inflammatory damage that's occurring," Woodruff said. "Our goal is really to slow the progression of the disease, so to target a component that's accelerating the disease and making the disease faster and more aggressive."
Clinical Translation Timeline
Professor Woodruff offered a cautiously optimistic timeline for translating the discovery into clinical testing. "With this knowledge, it's possible we could have an anti-inflammatory drug treatment for testing in MND patients within five years, possibly turning the disease into a long-term chronic condition rather than an acute terminal illness."
He acknowledged the work ahead: "There's still many steps to take, but we think it's an important step because this particular immune target that we've been studying for many years has never really been targeted before with a drug."
Global Collaboration and Funding
The breakthrough was made possible through an international collaboration involving researchers across Australia, Japan, South Korea, India, and Europe. Associate Professor Richard Clark emphasized the significance of this cross-border effort.
"This global effort demonstrates the power of cross-disciplinary and cross-border collaboration in tackling complex biomedical challenges," Dr. Clark said. "With this new ability to selectively target the C5aR2 (搜索) receptor, we can develop safer, more effective drugs with fewer side effects."
The research was funded by FightMND (搜索), the charity established by late AFL great Neale Daniher, who transformed the fight against MND after revealing his diagnosis in 2014. Daniher, who died in May this year following a 13-year battle with the disease, raised hundreds of millions of dollars for research through the charity's fundraising campaigns and was honored as Australian of the Year for his advocacy. Additional funding came through a National Health and Medical Research Council grant.
A Disease in the Spotlight
Motor neurone disease (搜索) kills two Australians every day, with an average prognosis of just two to three years from diagnosis. The announcement carries profound timing as the NRL launches its "Jai July" fundraising campaign for former South Sydney Rabbitohs and Queensland Maroons forward Jai Arrow, who was diagnosed with the incurable disease earlier this year at just 30 years old and was forced to retire.
Arrow is not the first Australian athlete to confront the disease. Former Queensland State of Origin enforcer Carl Webb was diagnosed in 2020 at age 39 and established the Carl Webb Foundation before his death in December 2023 at age 42. Former Hawthorn premiership player Geoff Ablett also died from MND in May this year.
The breakthrough follows another milestone from UQ researchers: the launch of Australia's first unified national database for Amyotrophic Lateral Sclerosis (搜索) (ALS), the most common form of MND. The database combines clinical information and biological samples from more than 1,300 Australian patients, creating a platform designed to accelerate earlier diagnosis, clinical trials, and the development of future treatments.